Roka Bioscience (ROKA) Tops Q3 EPS by 4c, Announces CFO Transition

Roka Bioscience (NASDAQ: ROKA) reported Q3 EPS of ($0.49), $0.04 better than the analyst estimate of ($0.53). Revenue for the quarter came in at $1.5 million versus the consensus estimate of $1.75 million.

Roka Bioscience, Inc. (NASDAQ: ROKA), a molecular diagnostics company focused on providing advanced testing solutions for the detection of foodborne pathogens, announced today the appointment of Lars Boesgaard as Vice President and Chief Financial Officer. Mr. Boesgaard, who joined Roka in 2009 and currently serves as Vice President, Finance and Controller, succeeds Steven Sobieski. Mr. Sobieski will continue his association with the Company as a Senior Advisor.

"Steve has been an outstanding contributor to Roka over the past six years," said Paul Thomas, Roka's CEO. "He helped build the strong financial foundation that we have in place today. I am confident that Lars' history with Roka will enable a seamless transition."

Mr. Boesgaard has 20 years of finance and accounting experience. He joined Roka in October 2009 as Controller and was promoted to Vice President, Finance in January 2012. Previously from 2007 to 2009, Mr. Boesgaard served as Vice President, Finance at Insulet Corporation. From 2004 to 2007, he was Senior Director, Financial Services at Alexion Pharmaceuticals, Inc. From 2000 to 2004, Mr. Boesgaard served in various financial roles at The Nielsen Company. From 1995 to 2000, he served in various financial roles at Novo Nordisk A/S.

For earnings history and earnings-related data on Roka Bioscience (ROKA) click here.

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• Vireo Growth completes acquisition of C21 Investments
• Intchains Group Ltd (ICG) PT Lowered to $2 at Benchmark Following 1H Results